A clear-eyed guide to GLP-1 slimming injections in Singapore — how they work, how well, how safe, the single biggest mistake to avoid, and how to protect your muscle and your face along the way.

A decade ago, the honest answer a doctor could give a patient who had “tried everything” was uncomfortable: eat less, move more, and accept that biology was quietly working against them. For the first time, that answer has changed. GLP-1 slimming injections have produced weight loss that, until recently, only surgery could deliver — and they have done it in enough people, publicly enough, that the entire conversation around weight has shifted.

The transformations are real, and for many patients they are genuinely life-changing — not only the number on the scale, but blood pressure, blood sugar, sleep quality, joint pain, and the simple ease of moving through a day. But the same tool, used carelessly, can leave someone worse off than doing nothing: stripped muscle, a stalled metabolism, a gaunt “deflated” face, and weight that returns with interest. The difference is entirely in how it is used.

This guide covers what these injections actually are, how they work, how well and how safely, the most common mistake people make with them, whether you will regain the weight, why weight loss is a medical win rather than a vanity project, and why the face sometimes needs a plan of its own. It is written for patients and grounded in the current clinical evidence.

What are GLP-1 slimming injections?

GLP-1 slimming injections are prescription weight-loss medications that copy a natural gut hormone your body releases after eating. They reduce appetite, slow how quickly the stomach empties, and increase the feeling of fullness, so you eat less without fighting constant hunger. In Singapore they are prescribed and supervised by a doctor — not sold over the counter.

The class is known as GLP-1 receptor agonists. Two are in common use for weight — semaglutide (given weekly) and liraglutide (given daily) — and both mimic glucagon-like peptide-1, one of the hormones your gut releases after a meal. The newest, tirzepatide, goes a step further: it is a dual agonist that copies two gut hormones at once (GLP-1 and GIP), which is part of why it tends to produce larger average weight loss. In Chinese these are often called 减肥针 (jiǎ n féi zhēn, “weight-loss injection”).

All of them are prescription-only medicines. Supply of the injectable forms in Singapore has been inconsistent, and daily and oral options exist as alternatives — which is one more reason the right choice is made with a doctor rather than assumed in advance. What matters far more than which specific product you are on is that you are properly assessed, correctly dosed, and monitored.

How GLP-1 injections work

They turn down appetite by amplifying a signal your body already uses. After a meal, your gut releases GLP-1, which tells the brain you are full, slows stomach emptying, and helps the pancreas manage blood sugar. Natural GLP-1 lasts only minutes. These medications are engineered copies that last for days — so the “I have had enough” signal stays switched on instead of fading between meals.

It is worth being precise about the supposed advantage here, because it is often overstated. GLP-1 injections are not “targeted drugs with no side effects” — GLP-1 receptors sit in the gut, pancreas, brain and even the heart, and several of the common side effects come precisely from that broad reach. The real advantage over the older generation of appetite suppressants is different and more honest: these medications work with your physiology rather than overriding it. Instead of a stimulant forcing appetite down against a body that fights back, they recruit the very same satiety machinery that a naturally lean person’s body uses after eating. That is why the effect feels less like white-knuckle willpower and more like simply wanting less food. As described in the New England Journal of Medicine, the drugs reduce food intake mainly by changing hunger and fullness signalling in specific regions of the brain.

It helps to think of losing weight as remodelling a building rather than demolishing it. The injection makes the remodelling possible by quietly removing your constant hunger — but it does not decide what gets removed and what stays standing. That decision is made by how you run the deficit, and we will return to it, because it is where almost every good and bad outcome is actually decided.

How much weight do people actually lose?

In the landmark trials the results were large enough that the researchers themselves described them as unusual for a weight-loss drug. A few reference points from the peer-reviewed evidence:

•   SURMOUNT-1 (New England Journal of Medicine, 2022): adults without diabetes taking tirzepatide lost, on average, up to about 22.5% of their body weight over 72 weeks at the highest dose — roughly 24 kg — compared with about 2.4% on placebo.
•   STEP-1 (New England Journal of Medicine, 2021): weekly semaglutide produced mean weight loss of about 14.9% over 68 weeks.
•   SURMOUNT-5 (New England Journal of Medicine, 2025), the head-to-head trial: tirzepatide averaged about 20.2% versus about 13.7% for semaglutide, and nearly half of the tirzepatide group lost 20% or more of their body weight.

Two caveats keep this honest. First, these are averages from supervised trials that included nutrition and activity counselling — the medication was a tool inside a programme, not a solo act. Second, individual results vary widely; some people respond strongly and some modestly. In supervised programmes, most appropriately selected patients achieve clinically meaningful weight loss and report better energy, mobility and confidence — but the magnitude differs from person to person, and no result is guaranteed.

The timeline is usually phased: reduced appetite in the first couple of weeks, more visible weight loss by weeks eight to twelve as the dose builds, and the steepest changes commonly between months three and six.

How safe are slimming injections?

For appropriately selected patients under medical supervision, GLP-1 medications have a well-characterised safety profile built on large randomised trials and several years of real-world use. Most side effects are gastrointestinal, mild to moderate, and concentrated in the early dose-escalation phase rather than spread across the whole treatment.

The rarer but important risks are worth naming plainly. Acute pancreatitis and gallstones can occur — gallstones are associated with rapid weight loss of any kind, not this drug class specifically. The medications are not suitable for people with a personal or family history of medullary thyroid carcinoma or MEN2 syndrome, those with a history of pancreatitis, or those with type 1 diabetes, and they call for caution in significant gastrointestinal disease such as gastroparesis. They are not used in pregnancy. This is exactly why a proper history and assessment matter — the safety of these drugs is largely a function of who is selected, how slowly the dose is raised, and how carefully they are monitored.

Put in perspective, the safety profile compares favourably with the health risks of the obesity and insulin resistance it treats. But “safe” is not a property of the vial — it is a property of good selection, sensible titration and ongoing monitoring, which is the doctor’s job, not the patient’s guesswork.

Side effects, and how we control them

Almost everyone tolerates these medications, but side effects are real and worth managing properly rather than gritting through. The guiding principle is simple: the dose that works with the fewest side effects is the right dose. Escalating slowly and not chasing the maximum solves most problems before they start.

Nausea and vomiting

The most common complaint, driven by slowed stomach emptying plus the drug’s central effects. It usually peaks during dose increases and settles as the body adjusts. It is controlled by titrating slowly, eating smaller and lower-fat meals, stopping at the first sign of fullness, and staying hydrated.

Constipation or diarrhoea

Slowed gut motility can push in either direction. Adequate fibre and fluids handle most cases; occasionally the titration is adjusted.

Reflux and feeling over-full

Because the stomach empties more slowly, large or late meals sit heavily. Smaller portions earlier in the day resolve it for most people.

Early fatigue or low energy

Often this is not the drug at all but under-eating or dehydration — a signal to eat enough protein and drink more, not to eat even less. Which leads directly to the biggest mistake of all.

The wrong way to use GLP-1: eating as little as possible

The single most common mistake is treating the appetite suppression as a licence to eat almost nothing. It feels efficient — the hunger is gone, so why not push the deficit as hard as possible? It is, in fact, the fastest way to ruin the result.

Here is where the remodelling analogy earns its keep. When you drop your intake too low, the body does not politely burn fat alone. It sheds whatever mass is quickest and cheapest to give up — and a large share of that is muscle, along with water and glycogen. The scale drops fast, which feels like winning, but you are gutting the structure rather than remodelling it.

The evidence is specific. Across GLP-1 trials, roughly a quarter to two-fifths of the weight lost is lean tissue — about 40% in the STEP-1 semaglutide body-composition sub-study and about 25% in the SURMOUNT-1 tirzepatide sub-study. Eating too little widens that fraction; adequate protein and resistance training narrow it dramatically, in some studies to almost nothing.

Why it matters compounds over time. Muscle is metabolically expensive tissue — lose it and your resting metabolic rate falls, so you burn fewer calories even at rest. That is precisely the engine you need running later, when you eventually reduce or stop the medication. On top of that, the dramatic early “whoosh” on the scale is disproportionately water and glycogen, not fat, so the mirror lags the numbers — and people wrongly conclude they must eat even less. The crash and the rebound are two ends of the same mistake.

The correct way to run it is unglamorous and effective: a moderate deficit, not a maximal one; protein of roughly 1.2–1.6 g per kilogram of body weight per day; and resistance training two to four times a week. Eat enough to train. That is the entire difference between remodelling your body and demolishing it.

Will I regain the weight?

If you stop and change nothing else, yes — most people regain a substantial share. GLP-1 medications manage a chronic condition; they do not cure it. This is not a failure of the drug, it is the nature of the problem.

The clearest evidence comes from SURMOUNT-4 (JAMA, 2023). After an initial run on tirzepatide, patients who switched to placebo regained about 14% of their body weight over the following year, while those who continued treatment lost a further 6.7%. A later analysis found that most people who stopped after losing at least 10% went on to regain a quarter or more of what they had lost — and their improvements in blood pressure, blood sugar and lipids reversed in step. Semaglutide trials show the same pattern. The reason is mechanical: the drug lowers your appetite set-point, so when you remove it, hunger returns to baseline while your now-smaller body needs fewer calories — a double bind that favours regain unless the surrounding habits have genuinely changed.

Which brings us to the part no injection repeals. Weight is ultimately governed by energy balance — what you eat versus what you burn. No medication and no dietary philosophy — keto, intermittent fasting, high-carb, low-fat — overrides that arithmetic; they are simply different ways of arriving at a deficit. The injection makes the deficit far easier to hold, but it does not replace having at least a rough idea of how much you are eating. The patients who keep their results are the ones who track their intake, even loosely, and who build the muscle that keeps their metabolism high. That is remodelling that stays standing — as opposed to a structure that collapses the moment the scaffolding comes down.

So the way to minimise rebound is decided long before you stop: do not crash (protect your muscle), use the “easy” appetite-suppressed window to build habits that will outlast the drug, keep training and eating enough protein, and plan the off-ramp — whether that is a slow taper or a low maintenance dose — deliberately with your doctor rather than quitting cold.

Weight loss is not just a cosmetic issue

It is tempting to file weight under appearance. Medically, that is a mistake. Excess weight — and the insulin resistance that usually travels with it — is an upstream driver of disease, not a vanity concern.

The list of conditions linked to obesity and insulin resistance is long and serious: type 2 diabetes, high blood pressure, abnormal cholesterol, cardiovascular disease, obstructive sleep apnoea, fatty liver disease, several cancers, osteoarthritis, polycystic ovary syndrome and fertility problems, and a background state of chronic low-grade inflammation. Insulin resistance in particular sits upstream of much of this cluster, quietly raising risk across multiple systems at once.

The flip side is that meaningful fat loss improves far more than the silhouette. In the trials, weight loss came with reductions in waist circumference, blood pressure, blood glucose and lipids, and semaglutide at a weight-management dose has cardiovascular-outcome evidence in defined patient groups. Losing 15–20% of body weight can move a person out of several risk categories simultaneously. In Singapore, where roughly one in ten adults lives with obesity and the associated conditions rank among the country’s leading chronic illnesses, that is why we treat this as medical weight management — not slimming.

What weight loss does for your appearance

Losing fat generally does make people look more attractive — but “attractive” and “younger” are not the same thing, and rapid loss can pull them apart. Faces at a healthy body weight are consistently rated as most attractive, and facial fullness is a cue the brain uses to read health: studies show a strong correlation between how full a face looks and a person’s measured body fat. Moving toward a healthy weight typically improves how attractive and how healthy a face reads.

There is an important exception, and it is not a marketing line. A 2024 systematic review of massive weight loss found that while modest loss tended to look more youthful, large and rapid loss often made faces look older even as overall attractiveness rose — because the facial fat pads deflate faster than skin and collagen can adapt. In other words, the body wins while the face can lose. That is precisely the mechanism behind the phenomenon everyone has now heard of.

“Ozempic face”: when weight loss ages the face

“Ozempic face” is the hollow, gaunt, prematurely aged look that can follow rapid GLP-1 weight loss. It is caused by loss of the facial fat pads combined with skin that cannot retract quickly enough to keep up.

The face is supported by discrete fat compartments — in the cheeks, temples, under-eyes and around the mouth — that give it soft, youthful fullness. Lose weight quickly and these deflate; the overlying skin, especially past your thirties, does not snap back at the same pace. The result is a flattened midface, hollow temples and under-eyes, and earlier jowling. Newer literature suggests GLP-1 medications may also influence skin biology directly, affecting the fibroblasts that produce collagen — so the goal of treatment is not simply to “fill” the face, but to rebuild its collagen scaffold.

This is where the remodelling idea pays off one last time. You spent months protecting the structure of your body; the face needs the same structural thinking, and restoration is sequenced, not slapped on:

•   Collagen-stimulating biostimulators — the material classes here are poly-L-lactic acid, calcium hydroxylapatite and polycaprolactone (PCL). These rebuild the dermal scaffold gradually and last the longest. For the diffuse volume loss of a weight-loss face, we favour PCL-based collagen stimulation, because it rebuilds structure rather than merely occupying space.
•   Hyaluronic acid fillers — for targeted, immediate volume in specific hollows such as the under-eye and midface. Precise, and reversible if needed.
•   Energy-based skin tightening — focused ultrasound (HIFU/MFU) and radiofrequency to address laxity as the skin retracts.

A 2026 paper in the Aesthetic Surgery Journal Open Forum describes exactly this layered strategy for GLP-1 weight-loss patients — biostimulators to rebuild the scaffold, hyaluronic acid for targeted volume, energy devices for laxity. The ideal results come from anticipating the change early, ideally beginning collagen support before or during the weight loss, rather than discovering a hollowed face at the end.

Our approach at Ozhean Zoey

We treat this as one continuous journey — the weight and the face together — under medical supervision, because the two are connected and are best planned as a whole rather than in sequence by accident.

Medical weight management, properly supervised

Treatment starts with assessment, not a prescription: history and suitability, screening for the contraindications above, baseline bloods and a body-composition scan. The dose is then raised slowly to the lowest effective level and reviewed regularly. This is medicine, not a product handed over a counter.

Protecting muscle and metabolism

Protein and resistance-training guidance and body-composition tracking are built into the programme, so that what you lose is fat — not the muscle that keeps your metabolism high and your results durable. This is the remodelling philosophy turned into a protocol.

Restoring the face on the right timeline

Volume and collagen restoration are sequenced deliberately: biostimulators to rebuild structure, hyaluronic acid where precision is needed, and skin tightening for laxity — planned early, dosed conservatively, and aimed at a natural rather than an over-filled look.

What drives the cost — and why we quote it in consultation

Under Singapore’s HSA medical advertising regulations, clinics are not permitted to publicly advertise prescription-only medicines or to display specific treatment prices. The notes below explain what drives cost; they are not a price list.

The cost of a medical weight-management plan is driven by which medication and dose you end up on — doses escalate over the first few months — by whether consultations and body-composition monitoring are included, and by whether facial restoration forms part of your plan. Because the medication is dosed to the individual and reviewed regularly, a meaningful figure only exists once you have been assessed. We confirm everything transparently at consultation.

Ready to take the next step?

Medical weight management and the aesthetic restoration that often follows it are both carried out by our registered doctors at Ozhean Zoey Medical & Aesthetic Clinic at TripleOne Somerset. If you are considering slimming injections — or you have already lost weight and want to restore facial volume the right way — the first step is an assessment so your plan is built around your body and your goals. Book a consultation here.

Frequently asked questions

Are slimming injections safe?

For appropriately selected patients under medical supervision, GLP-1 injections have a well-characterised safety profile from large trials and years of use. Most side effects are gastrointestinal and mild to moderate. Safety depends on proper selection, slow titration and monitoring — which is why assessment matters.

How much weight can I expect to lose on GLP-1 injections?

Trial averages range from about 15% of body weight on semaglutide to about 20–22% on tirzepatide over roughly 15 months, alongside diet and activity. Individual results vary considerably, and these figures come from supervised programmes rather than the medication alone.

What is the difference between semaglutide and tirzepatide?

Semaglutide activates one hormone pathway (GLP-1); tirzepatide activates two (GLP-1 and GIP). In the head-to-head SURMOUNT-5 trial, tirzepatide produced greater average weight loss. The right choice depends on your health profile, tolerance and what is available — a decision for your doctor.

How long do I need to stay on the injections?

GLP-1 medications manage a chronic condition rather than curing it, so many people use them long term or step down to a maintenance dose. How long is individual, and should be planned with your doctor around your response and your goals.

Will I regain the weight if I stop slimming injections?

If you stop and change nothing else, most people regain a substantial share — in SURMOUNT-4, patients who stopped regained about 14% over the following year. The way to minimise this is to protect muscle, build lasting habits during treatment, and plan the off-ramp deliberately.

Do slimming injections cause muscle loss?

Some lean-tissue loss accompanies any significant weight loss — roughly 25–40% of the total in GLP-1 trials. It is largely preventable. Adequate protein (about 1.2–1.6 g/kg/day) and resistance training shift the balance strongly back toward fat loss.

What is “Ozempic face” and can it be prevented?

“Ozempic face” is the hollow, aged look that can follow rapid weight loss, caused by deflation of the facial fat pads. It can be softened or prevented by losing weight at a sensible pace and by supporting collagen early with biostimulators, rather than waiting until the change is obvious.

Can I have fillers while I am still losing weight?

Often yes, and starting collagen support early can be an advantage — but timing matters, because the face is still changing. We plan the sequence around your weight-loss trajectory so the result stays balanced rather than needing frequent correction.

What are the most common side effects, and how long do they last?

Nausea, constipation or diarrhoea, and a sense of over-fullness are the usual ones, most pronounced during dose increases and easing as the body adjusts. Slow titration, smaller lower-fat meals and good hydration control the great majority of them.

Who is not suitable for GLP-1 injections?

People with a personal or family history of medullary thyroid carcinoma or MEN2, a history of pancreatitis, type 1 diabetes, or significant gastrointestinal conditions such as gastroparesis, and anyone pregnant. A full history at assessment is how we determine suitability.

Are weight-loss injections available over the counter in Singapore?

No. They are prescription-only medicines that must be prescribed by a doctor after a medical consultation and used under supervision. Anyone offering them without an assessment is not operating within the rules.

Do I still need to diet and exercise on the injection?

Yes — the injection makes a calorie deficit far easier to hold, but energy balance still governs the outcome, and training is what protects your muscle. The medication does the hard part of appetite; you still steer the direction.

The bottom line

GLP-1 slimming injections are an effective non-surgical weight-loss tool medicine has produced, and their benefits reach well beyond appearance into blood pressure, blood sugar, sleep and long-term disease risk. But they are a tool inside a programme, not a shortcut around one. Whether you end up better or worse off is decided by how the deficit is run — protecting muscle and metabolism rather than crashing them — and by whether the habits built during treatment can outlast it.

That is also why the choice of who prescribes them matters. The result depends on careful selection, slow titration, body-composition monitoring, and a plan for the face as volume changes — the whole journey, not just the prescription. If you are weighing up slimming injections, look for a doctor who treats it as medical weight management and who can look after your appearance as your body changes, so the version of you at the end is one you are glad to see in the mirror.